

## Late-onset hidradenitis suppurativa: A cluster analysis of the National Italian Registry IRHIS




*To the Editor:* Although hidradenitis suppurativa (HS) has a mean age of onset at about 22 years, late-onset HS can occur.<sup>1,2</sup> We analyzed data from 1100 consecutive, newly diagnosed patients with HS from 17 Italian outpatient clinics participating in the Italian Registry of HS (IRHIS).<sup>1</sup> Our aim was to assess the existence of clusters in the HS distribution in terms of age at onset and to evaluate differences between clusters with respect to demographics, clinical characteristics, and HS phenotypes. A detailed description of the methods used is reported in the Supplementary Materials (available via Mendeley at <https://data.mendeley.com/datasets/hstfswp5nv/1>). In this analysis, we relied on both k-means and Gaussian mixture model (GMM) clustering algorithms. Both methods indicated that a two-cluster model was best fitted to our data (Fig 1, Supplemental Table D) with early-onset HS peaking in the late teen years (mean = 17.0 years) and late-onset HS peaking at around the age of 40 years (mean = 38.4 years), with an optimal separation threshold at 28 years. Both univariate and age-adjusted and sex-adjusted multivariable logistic regression analyses were performed (Table D).

Patients were found to be similarly overweight in both early-onset and late-onset groups, with no sex differences found after adjusting for confounding variables. A significantly lower proportion of

patients in the late-onset group were smokers (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.40-0.93) and had a reported history of HS in first-degree relatives (OR, 0.31; 95% CI, 0.18-0.56). In addition, a shorter mean diagnostic delay and illness duration since the onset were observed in late-onset patients. Moreover, a less severe disease (according to the Sartorius score) was documented in the late-onset group compared with the early-onset group (OR, 0.42; 95% CI, 0.25-0.69). The frequency of involvement of the axillary-groin-buttocks and anogenital areas was similar between the 2 groups, whereas the neck and mammary locations were significantly and more frequently reported in the early-onset group ( $P < .05$ ). Similarly, follicular lesions, such as pilonidal cysts, were more frequently associated with early-onset HS (OR, 0.40; 95% CI, 0.20-0.77). Among additional HS-related features and comorbidities, atopic, seborrheic, and perioral dermatitis were all significantly associated with late-onset HS (OR, 5.46; 95% CI, 1.15-25.81).

Limitations of our analyses are the inclusion of tertiary care outpatient HS cases, the potential recall bias of self-reported age at onset, the absence of a formal validation on an independent dataset in order to test cluster stability, and the possibility of having residual confounding variables concerning the effect of age on the observed associations. Nevertheless, our analyses relied on a robust method for stratifying patients, and we were able to confirm the possibility of a late-onset HS variety in Italian patients in agreement with observations from another single study from North America.<sup>2,3</sup> The correlation



**Fig 1.** The distribution of age at hidradenitis suppurativa onset based on standard (A) and logarithmic scale (B) and with separation by identified clusters. The estimated distribution based on the two-component GMM is shown in (B). *GMM*, Gaussian mixture model.

**Table I.** Demographics and clinical characteristics of 1100 patients included in the study according to hidradenitis suppurativa onset

Variable	Early-onset HS		Late-onset HS		P value <sup>†</sup>	Multivariable analysis <sup>‡</sup>		
	n* = 843	%	n* = 257	%		N*	OR (95% CI)	P value
Sex								
Male	320	38.0%	110	42.8%	.16	430	1	.41
Female	523	62.0%	147	57.2%		670	0.86 (0.61-1.23)	
Age (years)								
Mean, SD	28.4	10.5	45.3	9.7	<.001	1100	1.14 (1.12-1.16) <sup>§</sup>	<.001
BMI (kg/m <sup>2</sup> )								
Mean, SD	26.5	5.7	28.7	6.5	<.001	1080	1.02 (0.99-1.05) <sup>§</sup>	.10
Education								
Elementary/lower secondary	223	26.5%	87	33.9%	.02	310	1	
Upper secondary	466	55.3%	118	45.9%		584	0.76 (0.50-1.15)	.20
University	154	18.3%	52	20.2%		206	0.74 (0.45-1.23)	.25
Smoker								
No	286	33.9%	64	24.9%	<.001	350	1	
Yes	517	61.3%	155	60.3%		672	0.61 (0.40-0.93)	.02
Ex	40	4.7%	38	14.8%		78	1.54 (0.79-3.01)	.20
HS in first-degree relatives								
No	573	77.0%	191	89.7%	<.001	764	1	
Yes	171	23.0%	22	10.3%		193	0.31 (0.18-0.56)	<.001
Age at HS onset (years)								
Mean, SD	17.0	4.6	38.4	8.7	-	-	-	-
HS duration since onset (years)								
Mean, SD	11.4	9.8	7.0	6.7	<.001	1100	0.48 (0.37-0.62) <sup>  ¶</sup>	<.001
Diagnostic delay (years)								
Mean, SD	7.6	8.4	4.2	4.9	<.001	1100	0.21 (0.16-0.28) <sup>  </sup>	<.001
Hurley								
I	303	35.9%	87	33.9%	.08	390	1	
II	399	47.3%	111	43.2%		510	1.05 (0.71-1.56)	.81
III	141	16.7%	59	23.0%		200	0.70 (0.43-1.16)	.17
Sartorius score								
Mean, SD	55.1	50.1	60.4	61.6	.80	1035	0.42 (0.25-0.69) <sup>  </sup>	.001
DLQI								
Mean, SD	12.9	7.8	14.3	8.4	.04	739	1.01 (0.99-1.04)	.30
Localization <sup>#</sup>								
Neck	50	5.9%	6	2.3%	.02	1100	0.27 (0.10-0.74)	.01
Mammary	189	22.4%	41	16.0%	.03		0.51 (0.31-0.82)	.006
Axillae	536	63.6%	145	56.4%	.04		0.79 (0.55-1.13)	.20
Buttocks	258	30.6%	87	33.9%	.33		0.85 (0.58-1.24)	.40
Groin	591	70.1%	178	69.3%	.80		0.79 (0.54-1.16)	.22
Anogenital area	76	9.0%	37	14.4%	.01		0.76 (0.45-1.28)	.31
Other	151	17.9%	42	16.3%	.56		1.04 (0.65-1.64)	.88

HS-related characteristics and comorbidities<sup>#</sup>

Acne conglobata	89	10.6%	23	8.9%	.45	1100	0.63 (0.34-1.18)	.15
Pilonidal cyst	109	12.9%	13	5.1%	<.001		0.40 (0.20-0.77)	.007
Folliculitis decalvans	9	1.1%	2	0.8%	1		0.62 (0.10-3.69)	.60
Other forms of acne	37	4.4%	6	2.3%	.14		0.80 (0.28-2.31)	.68
Dermatitis**	6	0.7%	5	1.9%	.14		5.46 (1.15-25.81)	.03
Psoriasis	11	1.3%	9	3.5%	.03		2.45 (0.85-7.09)	.10
Diabetes	2	0.2%	3	1.2%	.09		0.72 (0.09-5.92)	.76
Thyroid disease	11	1.3%	4	1.6%	.76		1.23 (0.30-5.05)	.77
Crohn disease	8	0.9%	3	1.2%	.72		0.47 (0.10-2.14)	.33

BMI, Body mass index; CI, confidence interval; DLQI, dermatology life quality index; HS, hidradenitis suppurativa; n, number of patients in each group; N, total number of patients included in multivariable analysis; OR, odds ratio; SD, standard deviation.

\*Numbers may not add up to the total due to missing data.

†Pearson's  $\chi^2$  test (or Fisher's exact test where required) and Mann-Whitney U tests were used in univariate analysis to compare nominal and continuous variables, respectively.

‡Results from logistic regression models including age and sex as covariates.

§OR per unit increase.

||OR of log<sub>10</sub> transformed data, representing OR per 10 units increase.

¶Adjusted for sex only.

#Multiple localizations/comorbidities were possible.

\*\*Including atopic, seborrheic, and perioral dermatitis.

between early-onset HS and a stronger familial history was previously reported in another retrospective study.<sup>4</sup> Distinct late-onset phenotypes have been reported in Crohn's disease, a chronic inflammatory condition sharing clinical and pathogenetic characteristics with HS. An age of onset of Crohn's disease after 60-65 years has been associated with stenosing disease, increased comorbidities, and medication burden.<sup>5</sup> The natural history and disease course in older adults with HS are unknown. Fixed-age cut-offs for the definition of early-onset and late-onset disease may prove challenging for clinical studies because of the skewed age distributions found in patients with HS. Cluster analysis may prove to be a useful strategy for addressing this issue and better defining the trajectories of comorbid conditions in HS. Future investigations assessing the significance of our phenotypes and outcomes in late-onset HS in terms of disease characteristics, prognostic factors, and treatments are recommended.

Simone Cazzaniga, PhD,<sup>a,b</sup> Elena Pezzolo, MD,<sup>a,c,d</sup> Simone Garcovich, PhD, MD,<sup>e,f</sup> Luigi Naldi, MD,<sup>a,d</sup> and the IRHIS Study Group\*

From the Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy<sup>a</sup>; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland<sup>b</sup>; Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands<sup>c</sup>; Department of Dermatology, San Bortolo Hospital, Vicenza, Italy<sup>d</sup>; Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy<sup>e</sup>; and Università Cattolica del Sacro Cuore, Dermatologia, Rome, Italy<sup>f</sup>

\*Vincenzo Bettoli (Dermatology Unit, Department of Oncology and Specialistic Medicines, Azienda Ospedaliera University of Ferrara, Italy), Damiano Abeni (Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy), Angelo V. Marzano (Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Physiopathology and Transplantation, Università degli Studi di Milano, Milan, Italy), Annalisa Patrizi (Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, Italy), Laura Atzori (Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy), Gabriella Fabbrocini (Dermatology Unit, Department of Clinical Medicine and Surgery, University of Federico II, Naples, Italy), Annamaria Offidani

(Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic University of Marche Region, Ancona, Italy), Claudia Lasagni (Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy), Valentina Dini (Department of Dermatology, University of Pisa, Pisa, Italy), Marzia Caproni (Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy), Serafinella Patrizia Cannavò (Dermatology Unit, Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy).

Drs Cazzaniga and Pezzolo contributed equally to this article.

Funding sources: None.

IRB approval status: Not applicable.

Reprints not available from the authors.

Correspondence to: Elena Pezzolo, MD, Study Center of the Italian Group for Epidemiological Research in Dermatology (GISED), Via Clara Maffei 4, 24121 Bergamo, Italy

E-mail: [elena.pezzolo@aulss8.veneto.it](mailto:elena.pezzolo@aulss8.veneto.it)

#### Conflicts of interest

None disclosed.

#### REFERENCES

1. Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the National Italian Registry IRHIS. *J Invest Dermatol*. 2020. <https://doi.org/10.1016/j.jid.2020.08.032>.
2. Naik HB, Paul M, Cohen SR, Alavi A, Suárez-Fariñas M, Lowes MA. Distribution of self-reported hidradenitis suppurativa age at onset. *JAMA Dermatol*. 2019;155(8):971-973.
3. Jung YG, Kang MS, Heo J. Clustering performance comparison using K-means and expectation maximization algorithms. *Biotechnol Biotechnol Equip*. 2014;28(suppl1):S44-S48.
4. Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. *J Am Acad Dermatol*. 2015;72(3):485-488.
5. Viola A, Monterubbianesi R, Scalisi G, et al. Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. *Eur J Gastroenterol Hepatol*. 2019;31(11):1361-1369.

<https://doi.org/10.1016/j.jaad.2021.02.075>